Pharmacology
Original Paper
Peripheral κ-Opioid Agonist, ICI 204448, Evokes Hypothermia in Cold-Exposed RatsRawls S.M.a · Ding Z.b · Gray A.M.c · Cowan A.baDepartment of Pharmaceutical Sciences, Temple University School of Pharmacy and bDepartment of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, Pa., and cGlaxoSmithKline, Research Triangle Park, N.C., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: July 13, 2004
Accepted: November 12, 2004
Published online: May 26, 2005
Issue release date: May 2005
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)
For additional information: https://www.karger.com/PHA
Abstract
ICI 204448, a selective ĸ-opioid agonist with limited CNS access, can be used to discriminate central and peripheral opioid actions on physiological systems such as pain and thermoregulation. Therefore, we investigated the effect of ICI 204448 (2.5, 5, and 10 mg/kg, s.c.) on male Sprague-Dawley rats exposed to ambient temperatures of 5, 20, or 32°C. ICI 204448 did not alter the body temperature of rats maintained at 20 or 32°C. However, 5 and 10 mg/kg of ICI 204448 evoked significant hypothermia in rats exposed to 5°C. The i.c.v. administration of nor-BNI, a ĸ-opioid antagonist, did not affect the hypothermia produced by the systemic injection of ICI 204448. Thus, an involvement of brain ĸ-opioid receptors in ICI 204448-evoked hypothermia is unlikely. The present data demonstrate for the first time that ICI 204448 produces hypothermia in cold-exposed rats and suggest that the role of peripheral ĸ-opioid receptors in thermoregulation becomes more significant at cold ambient temperatures.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Barber A, Gottschlich R: Opioid agonists and antagonists: An evaluation of their peripheral actions in inflammation. Med Res Rev 1992;12:525–562.
- Dragonetti M, Bianchetti A, Sacilotto R, Giudice A, Ferrarese N, Cattaneo C, Manara L: Levallorphan methyl iodide (SR 58002), a potent narcotic antagonist with peripheral selectivity superior to that of other quaternary compounds. Life Sci 1983;33:477–480.
- Notarnicola A, Landi M, Bianchi G, Tavani A: Relative ability of N-methyl nalorphine and N-methyl levallorphan to prevent antinociception and intestinal transit inhibition in morphine-treated rats. Life Sci 1983;33:481–484.
- Shaw JS, Carroll JA, Alcock P, Main BG: ICI 204448: a κ-opioid agonist with limited access to the CNS. Br J Pharmacol 1989;96:986–992.
- Barber A, Bartoszyk GD, Bender HM, Gottschlich R, Greiner HE, Harting J, Mauler F, Minck KO, Murray RD, Simon M: A pharmacological profile of the novel, peripherally-selective κ-opioid receptor agonist, EMD 61753. Br J Pharmacol 1994;113:1317–1327.
- Barber A, Bartoszyk GD, Greiner HE, Mauler F, Murray RD, Seyfried CA, Simon M, Gottschlich R, Harting J, Lues I: Central and peripheral actions of the novel κ-opioid receptor agonist, EMD 60400. Br J Pharmacol 1994;111:843–851.
- Keita H, Kayser V, Guilbaud G: Antinociceptive effect of a κ-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy. Eur J Pharmacol 1995;277:275–280.
- Rawls SM, Adler MW, Gaughan JP, Baron A, Geller EB, Cowan A: NMDA receptors modulate morphine-induced hyperthermia. Brain Res 2003;984:76–83.
- Adler MW, Geller EB: Hypothermia and poikilothermia induced by a κ-agonist opioid and a neuroleptic. Eur J Pharmacol 1987;140:233–237.
- Spencer RL, Hruby VJ, Burks TF: Body temperature response profiles for selective μ-, δ- and κ-opioid agonists in restrained and unrestrained rats. J Pharmacol Exp Ther 1988;246:92–101.
- Geller EB, Hawk C, Keinath SH, Tallarida RJ, Adler MW: Subclasses of opioids based on body temperature change in rats: Acute subcutaneous administration. J Pharmacol Exp Ther 1983;225:391–398.
- Ginawi OT: Possible involvement of opioid receptors in moclobemide-induced hypothermia in mice. Pharmacol Res 2003;48:237–240.
-
Romanovsky AA, Shido O, Ungar AL, Blatteis CM: Peripheral naloxone attenuates lipopolysaccharide fever in guinea pigs by an action outside the blood-brain barrier. Am J Physiol 1994;266:R1824–R1831.
- Baker AK, Meert TF: Functional effects of systemically administered agonists and antagonists of μ-, δ-, and κ-opioid receptor subtypes on body temperature in mice. J Pharmacol Exp Ther 2002 302:1253–1264.
- Jones DN, Holtzman SG: Long term κ-opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol 1992, 215:345–348.
- Ghosh S, Geller EB, Adler MW: Interaction of cholecystokinin and somatostatin with a selective μ-opioid agonist and μ- and κ-antagonists in thermoregulation. Brain Res 1997;745:152–157.
- Handler CM, Price RW, Geller EB, Adler MW: Effect of μ-selective opioid antagonists on MIP-1β and IL-1β-induced fever. Ann NY Acad Sci 1998, 856:270–273.
- Chen X, McClatchy DB, Geller EB, Liu-Chen L, Tallarida RJ, Adler MW: Possible mechanism of hypothermia induced by intracerebroventricular injection of orphanin FQ/nociceptin. Brain Res 2001;904:252–258.
- Salmi P, Kela J, Arvidsson U, Wahlestedt C: Functional interactions between δ- and μ-opioid receptors in rat thermoregulation. Eur J Pharmacol 2003;458:101–106.
- Handler CM, Piliero TC, Geller EB, Adler MW: Effect of ambient temperature on the ability of μ-, κ- and δ-selective opioid agonists to modulate thermoregulatory mechanisms in the rat. J Pharmacol Exp Ther 1994;268:847–855.
Article / Publication Details
Received: July 13, 2004
Accepted: November 12, 2004
Published online: May 26, 2005
Issue release date: May 2005
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)
For additional information: https://www.karger.com/PHA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
